参考文献/References:
[1] Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours
in adults [J]. Lancet, 2012, 379(9830): 1984-1996.
[2] 刘 仁，王 峻，连海伟. 原发性中枢神经系统淋巴瘤的
诊治分析[J]. 中国临床神经外科杂志，2014，19：68-73.
[3] Ahluwalia MS, Peereboom DM. Primary central nervous
system lymphoma [J]. Curr Treat Options Neurol, 2010, 12
(4): 347-359.
[4] Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS
lymphoma of T-cell origin: a descriptive analysis from the
international primary CNS lymphoma collaborative group
[J]. J Clin Oncol, 2005, 23: 2233-2239.
[5] Schabet M. Epidemiology of primary CNS lymphoma [J]. J
Neurooncol, 1999, 43(3): 199-201.
[6] Villano JL, Koshy M, Shaikh H, et al. Age, gender, and
racial differences in incidence and survival in primary CNS
lymphoma [J]. Br J Cancer, 2011, 105(9): 1414-1418.
[7] Citterio G, Ferreri AJ, Reni M, et al. Current uses of
radiation therapy in patients with primary CNS lymphoma
[J]. Expert Rev Anticancer Ther, 2013, 13(11): 1327-1337.
[8] Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lym-
phoma of the brain: can high dose, large volume radiation
therapy improve survival--report on a prospective trial
by the Radiation Therapy Oncology Group (RTOG): RTOG
8315 [J]. Int J Radiat Oncol Biol Phys, 1992, 23(1): 9-17.
[9] Shibamoto Y, Hayabuchi N, Hiratsuka J, et al. Is whole-
brain irradiation necessary for primary central nervous
system lymphoma: patterns of recurrence after partial-
brain irradiation [J]. Cancer, 2003, 97(1): 128-133.
[10] Kim BH, Kim IH, Park SH, et al. Low-dose whole brain
radiotherapy with tumor bed boost after methotrexate-based
chemotherapy for primary central nervous system lymphoma
[J]. Cancer Res Treat, 2014, 46(3): 261-269.
[11] Blay JY, Conroy T, Chevreau C, et al. High-dose methotre-
xate for the treatment of primary cerebral lymphomas: ana-
lysis of survival and late neurologic toxicity in a retrospec-
tive series [J]. J Clin Oncol, 1998, 16(3): 864-871.
[12] Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term
follow-up of high-dose methotrexate-based therapy with
and without whole brain irradiation for newly diagnosed
primary CNS lymphoma [J]. J Clin Oncol, 2006, 24(28):
4570-4574.
[13] Thiel E, Korfel A, Martus P, et al. High-dose methotrexate
with or without whole brain radiotherapy for primary CNS
lymphoma (G-PCNSL-SG-1): a phase 3, randomised,
non-inferiority trial [J]. Lancet Oncol, 2010, 11(11): 1036-
1047.
[14] Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed
by high-dose chemotherapy with TBC and autologous stem-
cell transplant for newly diagnosed primary CNS lymphoma
[J]. Blood, 2015, 125(9): 1403-1410.
[15] Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central
nervous system recurrence of systemic lymphoma in the era
of stem cell transplantation--an International Primary
Central Nervous System Lymphoma Study Group project [J].
Haematologica, 2013, 98(5): 808-813.
[16] Morris PG, Correa DD, Yahalom J, et al. Rituximab, metho-
trexate, procarbazine, and vincristine followed by consoli-
dation reduced-dose whole-brain radiotherapy and cytara-
bine in newly diagnosed primary CNS lymphoma: final
results and long-term outcome [J]. J Clin Oncol, 2013,
31(31): 3971-3979.
[17] Ferreri AJ, Verona C, Politi LS, et al. Consolidation radio-
therapy in primary central nervous system lymphomas:
impact on outcome of different fields and doses in patients
in complete remission after upfront chemotherapy [J]. Int J
Radiat Oncol Biol Phys, 2011, 80(1): 169-175.
[18] Ahles AT. Brain vulnerability to chemotherapy toxicities [J].
Psychooncology, 2012, 21(11): 1141-1148.
[19] Correa DD, Shi W, Abrey LE, et al. Cognitive functions in
primary CNS lymphoma after single or combined modality
regimens [J]. Neuro Oncol, 2012, 14(1): 101-108.
[20] Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemo-
therapy and immunotherapy in patients with newly diagno-
sed primary CNS lymphoma: CALGB 50202 (Alliance
50202) [J]. J Clin Oncol, 2013, 31(25): 3061-3068.
[21] Correa DD, Root JC, Moore D, et al. A prospective evalua-
tion of changes in brain structure and cognitive functions in
adult stem cell transplant recipients [J]. Brain Imaging
Behav, 2013, 7(4): 478-490.
[22] Soussain C, Choquet S, Fourme E, et al. Intensive chemo-
therapy with thiotepa, busulfan and cyclophosphamide and
hematopoietic stem cell rescue in relapsed or refractory
primary central nervous system lymphoma and intraocular
lymphoma: a retrospective study of 79 cases [J]. Haemato-
logica, 2012, 97(11): 1751-1756.